Stevanato Group S.p.A.: Initiation Of Coverage – The Rising Demand for Biologics Catalyzing Growth? 

Stevanato Group reported a positive 2023 stating a growth of 10% or 11% in constant currency terms. As per Executive Chairman of the company, Franco Stevanato, the group has seen continued growth despite the inflation uncertainty and ongoing supply chain issues. According to the chairman, while these dynamics have been challenging to navigate, they have simultaneously facilitated the growth of high-value solutions within Stevanato Group’s business model. The group has continued to make substantial investments to expand capacity and meet increasing market demand, a move they rehearse will drive its organic growth in the future.